MP11-01 PRESCRIPTION PATTERNS OF SYSTEMIC THERAPY IN THE MANAGEMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP11-01 PRESCRIPTION PATTERNS OF SYSTEMIC THERAPY IN THE MANAGEMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER Joseph Black, David Einstein, Xin Gao, Xiao Wei, Brendan Connell, Nick Kamkari, Boris Gershman, and Aria Olumi Joseph BlackJoseph Black More articles by this author , David EinsteinDavid Einstein More articles by this author , Xin GaoXin Gao More articles by this author , Xiao WeiXiao Wei More articles by this author , Brendan ConnellBrendan Connell More articles by this author , Nick KamkariNick Kamkari More articles by this author , Boris GershmanBoris Gershman More articles by this author , and Aria OlumiAria Olumi More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003226.01AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Metastatic castration-sensitive prostate cancer (mCSPC) is an incurable disease. Although androgen deprivation therapy (ADT) remains the backbone treatment for patients with mCSPC, multiple randomized studies since 2015 have demonstrated that treatment intensification with the addition of taxanes and/or novel hormonal therapies (NHT) confers significantly improved overall survival. This adds complexity for providers with developing an individual therapeutic approach for patients with mCSPC. Provider prescription patterns for mCSPC are heterogenous, which may present barriers for patients in receiving newer interventions. To investigate this, we conducted a retrospective analysis on the prescription utilization patterns of clinicians initiating treatment for patients with mCSPC. METHODS: Pharmacy and claims data were queried from 2015-2022 to identify patients with prostate cancer (PCa). The dataset includes 18 million US cancer patients, including Medicaid, Medicare, Medicare Part D, and cash transactions. Patients with mCSPC were identified using at minimum two ICD9/10 diagnosis codes and/or medications on separate days. Drug classes analyzed include NHT, 1st-generation anti-androgens, chemotherapy, and LHRH monotherapy. Prescription rates of each class of drug were stratified by patient and provider baseline characteristics. RESULTS: NHT prescription has increased, while chemotherapy, first generation anti-androgens, and LHRH monotherapy have either remained unchanged or decreased since 2015. No variation in prescription patterns were observed between urban and rural settings. Medical oncologists were more likely to prescribe NHT than urologists (45% vs. 19%), whereas urologists were more likely to prescribe LHRH monotherapy (69% v 38%). CONCLUSIONS: Since 2015, NHT utilization and treatment intensification has nationally increased for mCSPC and prescription patterns do not vary between rural and urban settings. When compared to urologists, medical oncologists have more readily incorporated newer therapeutics for mCSPC and decreased the usage of LHRH monotherapy for patients with mCSPC. These data represent a potential area for growth for urologists in the treatment of mCSPC. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e123 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Joseph Black More articles by this author David Einstein More articles by this author Xin Gao More articles by this author Xiao Wei More articles by this author Brendan Connell More articles by this author Nick Kamkari More articles by this author Boris Gershman More articles by this author Aria Olumi More articles by this author Expand All Advertisement PDF downloadLoading ...